Treatment of mediastinitis due to methicillin-resistant Staphylococcus aureus in a renal dysfunction patient undergoing adjustments to the linezolid dose.
This study is the first case report of the treatment of methicillin-resistant Staphylococcus aureus (MRSA) mediastinitis using therapeutic drug monitoring of the serum and wound exudate concentrations of linezolid in a renal dysfunction patient. In the present study, the serum trough concentration of linezolid was maintained between 2 and 7 μg/mL. Therapeutic drug monitoring dosage adjustments may be especially useful in patients with renal dysfunction and severe MRSA infection.
Department of Medical Pharmaceutics, Graduate School of Medicine and Pharmaceutical Sciences for Research, University of Toyama, Japan.
Yasuhiro
Y
Tsuji
Masato
M
Tashiro
Nobuyuki
N
Ashizawa
Yukio
Y
Ota
Hayato
H
Obi
Saori
S
Nagura
Munetoshi
M
Narukawa
Kazuaki
K
Fukahara
Naoki
N
Yoshimura
Hideto
H
To
Yoshihiro
Y
Yamamoto
D000081:Acetamides / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D000368:Aged; D006348:Cardiac Surgical Procedures / Q000009:adverse effects; D006801:Humans; D000069349:Linezolid; D008297:Male; D008480:Mediastinitis / Q000188:drug therapy* / Q000453:epidemiology; D055624:Methicillin-Resistant Staphylococcus aureus; D023303:Oxazolidinones / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D011183:Postoperative Complications / Q000382:microbiology*; D051437:Renal Insufficiency / Q000453:epidemiology; D013203:Staphylococcal Infections / Q000188:drug therapy; D013921:Thrombocytopenia / Q000139:chemically induced*
D000081:Acetamides; D023303:Oxazolidinones; D000069349:Linezolid